Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Raw Materials (2019 - 2025)

Karyopharm Therapeutics' Raw Materials history spans 7 years, with the latest figure at $628000.0 for Q4 2025.

  • For Q4 2025, Raw Materials fell 12.78% year-over-year to $628000.0; the TTM value through Dec 2025 reached $628000.0, down 12.78%, while the annual FY2025 figure was $628000.0, 12.78% down from the prior year.
  • Raw Materials reached $628000.0 in Q4 2025 per KPTI's latest filing, roughly flat from $630000.0 in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $2.6 million in Q1 2022 to a low of $261000.0 in Q2 2022.
  • Average Raw Materials over 5 years is $1.0 million, with a median of $720000.0 recorded in 2024.
  • Peak YoY movement for Raw Materials: plummeted 85.7% in 2022, then soared 330.65% in 2023.
  • A 5-year view of Raw Materials shows it stood at $1.8 million in 2021, then dropped by 23.76% to $1.4 million in 2022, then tumbled by 59.64% to $553000.0 in 2023, then skyrocketed by 30.2% to $720000.0 in 2024, then decreased by 12.78% to $628000.0 in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Raw Materials are $628000.0 (Q4 2025), $630000.0 (Q3 2025), and $477000.0 (Q2 2025).